Lilly(Eli) & Company
NYSE: LLY
$789.13
+$12.75 (+1.6%)
Real Time Data Delayed 15 Min.
LLY Articles
Incyte and Eli Lilly will be under the microscope next week as the FDA will decide the fate of their rheumatoid arthritis treatment.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include BBVA, Bed Bath & Beyond, Dropbox, Eli Lilly, Netflix, Procter & Gamble, Splunk and Starbucks.
Published:
Last Updated:
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
Published:
Last Updated:
The January 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published:
Last Updated:
Four large-cap pharmaceutical leaders are rated Overweight at JPMorgan, and all make sense for growth accounts looking for some safety and income.
Published:
Last Updated:
Eli Lilly reported better-than-expected fourth-quarter financial results before the markets opened on Wednesday.
Published:
Last Updated:
The January 12 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Published:
Last Updated:
With the market trading at very extended valuations, and the S&P 500 on the longest streak ever without a 5% correction, it may make sense to move to some safer higher ground.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include Apple, BHP Billiton, CBS, Eli Lilly, GE, Halliburton, IBM, Schlumberger and Verizon.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Amazon.com, Boeing, Chesapeake Energy, Eli Lilly, Gilead Sciences, Micron Thecnology, NVIDIA, Procter & Gamble...
Published:
Last Updated:
The December 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Published:
Last Updated:
Credit Suisse has put together a list of biopharma companies in its coverage universe that stand to make significant moves in 2018.
Published:
Last Updated: